The Kaplan-Meier plotter survival analysis also showed that FoxM1 mRNA high expression was correlated to shorter DMFS in all BC patients (HR = 1.85, p = 5.8e–10) (Figure 4D), specifically in BC patients with Luminal A tumors (HR = 2.09, p = 1.0e–6) and Luminal B tumors (HR = 1.65, p = 0.0061) (Figure 4E–4F). This evidence concerns the gene FOXM1 and breast cancer.